Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge

Journal of Virology

Volumn 75, Issue 22, 2001, Pages 11079-11087

  Kahn, J S ^a   Roberts, A ^a   Weibel, C ^a   Buonocore, L ^a   Rose, J K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS ANTIGEN; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUSION GENE; HUMAN; HUMAN CELL; IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VACCINATION; VESICULAR STOMATITIS VIRUS; VIRION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, VIRAL; BASE SEQUENCE; CELL LINE; CRICETINAE; FEMALE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VESICULAR STOMATITIS-INDIANA VIRUS; VIRAL PROTEINS; VIRAL VACCINES; VIRUS REPLICATION;

EID: 0034756215     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.22.11079-11087.2001     Document Type: Article

References (57)

1. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis
2. Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay
3. Acute respiratory infections: The forgotten pandemic
4. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
5. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: Clinical and immune responses to subsequent natural infection in children
6. Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice
7. Identification of variable domains of the attachment (G) protein of subgroup A respiratory syncytial viruses
8. Respiratory syncytial virus
9. Oligomerization and post-translational processing of glycoprotein G of human respiratory syncytial virus: Altered O-glycosylation in the presence of brefeldin
10. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10
11. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells
12. Respiratory viral infections in immunocompetent and immunocompromised persons
13. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly
14. Antigenic heterogeneity of the attachment protein of bovine respiratory syncytial virus
15. Epidemiology of acute lower respiratory disease in children
16. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level
17. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia
18. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia
19. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children
20. Respiratory syncytial viral infection in children with compromised immune function
21. Respiratory syncytial virus pneumonia among the elderly: An assessment of disease burden
22. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children
23. Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus
24. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life
25. Intracellular IFN-gamma expression in natural killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial virus infection
26. Th1 and Th2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus
27. Antigenic relatedness between glyco-proteins of human respiratory syncytial virus subgroups A and B: Evaluation of the contributions of F and G glycoproteins to immunity
28. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glyco-proteins: RSV fusion protein can mediate infection and cell fusion
29. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine
30. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: Clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant
31. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children
32. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine
33. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus
34. Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: Distinct mechanisms of action in vivo
35. The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. II. Monoclonal antibodies of nonneutralizing and cross-reactive epitopes of Indiana and New Jersey serotypes
36. Respiratory syncytial viral infection in infants with congenital heart disease
37. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old
38. Mechanism of lung injury in cotton rats immunized with formalin-inactivated respiratory syncytial virus
39. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis
40. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat
41. Attenuated vesicular stomatitis viruses as vaccine vectors
42. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge
43. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1
44. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies
45. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection
46. Bronchiolitis-associated hospitalizations among US children, 1980-1996
47. Characteristics of fusion of respiratory syncytial virus with HEp-2 cells as measured by R18 fluorescence dequenching assay
48. Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge
49. Genetic diversity of the attachment protein of subgroup B respiratory syncytial viruses
50. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old
51. Analysis of the respiratory syncytial virus fusion protein using monoclonal and polyclonal antibodies
52. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis
53. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern
54. Structure and cell surface maturation of the attachment glycoprotein of human respiratory syncytial virus in a cell line deficient in O glycosylation
55. Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice
56. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in inancy